2018 American Transplant Congress
Sirolimus Use Improves Cancer-Free Survival Following Transplantation: A Single Center 10-Year Analysis
Introduction:In previous published results, we showed that the use of Sirolimus-based immunosuppression regimens had equivalent patient and graft 10-year survival compared to historical controls maintained…2017 American Transplant Congress
Differential Effects of the Novel ATP-Competitive mTOR Inhibitor (TORKinib) AZD2014 and Rapamycin on Alloimmunity and Transplant Survival.
Surgery, Thomas Starzl Transplantation Institute, Pittsburgh, PA
Background: Rapamycin (RAPA), is an immunosuppressive agent that inhibits the mechanistic target of Rapamycin (mTOR), the kinase subunit of two mTOR- containing complexes (mTORC1 and…2017 American Transplant Congress
Impact of Everolimus Added to a De Novo Belatacept Regimen on the Risk of BK Viremia After Kidney Transplant.
IntroductionBK viremia is a common complication following kidney transplantation. In vitro data suggest that inhibition of the mTOR–SP6-kinase pathway prevents expression of early viral genes…2017 American Transplant Congress
Alternations in Amplitude of Low Frequency Fluctuation in Renal Allograft Recipients That Received Tacrolimus or Sirolimus: An fMRI Study.
Objective The side-effects of resting tremor was common in renal transplant receipts receive tacrolimus. But the mechanism of this side-effect was unknown. This study want…2017 American Transplant Congress
DC-SIGN Functionalized Porous Silicon Nanoparticles Targeting to Human and Non-Human Primate Dendritic Cells.
Porous silicon (pSi) nanoparticles, modified to specifically target DC, provide a novel platform to carry and deliver immunosuppressive drugs. The aim was to conjugate DC-SIGN…2017 American Transplant Congress
Determinants of Successful Use of Sirolimus in Renal Transplantation.
Sirolimus (SLR) is an established component in the immunosuppressive treatment after renal transplantation.The side effects of SLR differ from other immunosuppressants and may limit its…2017 American Transplant Congress
Systemic Meta-Analysis: Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients?
Aim: This meta-analysis focuses on the current evidence of renal graft functioning and graft survival following early conversion to mTOR inhibitors with or without CNI…2017 American Transplant Congress
mTOR Inhibitor and Low-Dose Tacrolimus in Pediatric Kidney Transplant (PKT): 9-Years Data of a Bi-Therapy Treatment.
Pediatric Nephrology, Hosptal Vall d´Hebron, Barcelona, Spain
INTRODUCTIONNephrotoxicity , serious infectious, or malignancy risk , curtails tacrolimus use in PKT . However, based on potential antiviral and antitumoral actions of mTOR inhibitor…2017 American Transplant Congress
Sirolimus Prolonged Survival After Living Donor Liver Transplantation for HCC Beynd Milan Criteria; Outcome of a Multicenter Prospective Randomized Phase II Trial (ClinicalTrials.gov Identifier: NCT01374750).
Background:It is unclear whether the reported benefit of mTORi in LT for HCC is from direct effect of mTOR inhibitors. We aimed to compare directly…2016 American Transplant Congress
Effect of Isolated Intraperitoneal Sirolimus Treatment on the Kidneys of C57BL/6 Mice.
Sirolimus, a mammalian target of rapamycin inhibitor, is widely used in transplantation. However, the mechanism by which sirolimus induces adverse effects such as proteinuria and…
American Transplant Congress abstracts